MCF2L2

Across TCGA pan-cancer cohorts, MCF2L2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MCF2L2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MCF2L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCF2L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and PRAD are the cancer types where MCF2L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
UCEC	OS	Median	All	0.940	0.631	.006	30	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MCF2L2–KIRP (OS)

Open the KIRP breakdown →